Article
Efficacy of increased-dose erlotinib for central nervous system metastases in non-small cell lung cancer patients with epidermal growth factor receptor mutation.
Cancer chemotherapy and pharmacology - 1 Oct 2011
Togashi Yosuke, Masago Katsuhiro, Fukudo Masahide, Tsuchido Yasuhiro, Okuda Chiyuki, Kim Young Hak, Ikemi Yasuaki, Sakamori Yuichi, Mio Tadashi, Katsura Toshiya, Mishima Michiaki
Abstract excerpt
PURPOSE: Recent reports indicate that refractory central nervous system (CNS) metastases of non-small cell lung cancer (NSCLC) are improved by high-dose gefitinib or erlotinib administration. We describe a Japanese woman with NSCLC and CNS metastases who was resistant to 75 mg daily erlotinib, but the metastases were improved by 150 mg daily erlotinib. We investigated the plasma and CSF concentrations of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.